{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:11:51Z","timestamp":1770999111948,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T00:00:00Z","timestamp":1462233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.vascn.2016.04.012","type":"journal-article","created":{"date-parts":[[2016,5,3]],"date-time":"2016-05-03T05:45:32Z","timestamp":1462254332000},"page":"306-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys"],"prefix":"10.1016","volume":"81","author":[{"given":"Simon","family":"Authier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael V.","family":"Accardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Paquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myl\u00e8ne","family":"Pouliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Arezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. John","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Gerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence T.","family":"Friedhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Weis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2016.04.012_bb0005","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/105504999305848","article-title":"Treatment of acute opioid withdrawal with ibogaine","volume":"8","author":"Alper","year":"1999","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.vascn.2016.04.012_bb0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","article-title":"The ibogaine medical subculture","volume":"115","author":"Alper","year":"2008","journal-title":"Journal of Ethnopharmacology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.vascn.2008.12.003","article-title":"Video-electroencephalography in conscious nonhuman primate using radiotelemetry and computerized analysis: Refinement of a safety pharmacology model","volume":"60","author":"Authier","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.04.012_bb0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.vascn.2014.10.004","article-title":"Reprint of \"Effects of amphetamine, diazepam and caffeine on polysomnography (EEG, EMG, EOG)-derived variables measured using telemetry in cynomolgus monkeys\"","volume":"70","author":"Authier","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.04.012_bb0025","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vascn.2014.07.005","article-title":"Telemetry video-electroencephalography (EEG) in rats, dogs and non-human primates: methods in follow-up safety pharmacology seizure liability assessments","volume":"70","author":"Bassett","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.04.012_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0099-9598(01)56009-5","article-title":"Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine","volume":"56","author":"Baumann","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-3565(24)29567-7","article-title":"In vivo neurobiological effects of ibogaine and its O-desmethyl metabolite, 12-hydroxyibogamine (noribogaine), in rats","volume":"297","author":"Baumann","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2016.04.012_bb0040","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(95)00247-I","article-title":"Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity","volume":"279","author":"Bowen","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1369-1600.2010.00251.x","article-title":"Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration","volume":"15","author":"Carnicella","year":"2010","journal-title":"Addiction Biology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0050","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0269881115584461","article-title":"Noribogaine reduces nicotine self-administration in rats","volume":"29","author":"Chang","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/1752-1947-5-449","article-title":"Changes in physiological tremor associated with an epileptic seizure: A case report","volume":"5","author":"Daneault","year":"2011","journal-title":"Journal of Medical Case Reports"},{"key":"10.1016\/j.vascn.2016.04.012_bb0060","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-94-017-8914-1_1","article-title":"How can we identify ictal and interictal abnormal activity?","volume":"813","author":"Fisher","year":"2014","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0006-8993(96)00056-X","article-title":"18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats","volume":"719","author":"Glick","year":"1996","journal-title":"Brain Research"},{"key":"10.1016\/j.vascn.2016.04.012_bb0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1749-6632.2000.tb05211.x","article-title":"18-Methoxycoronaridine (18-MC) and ibogaine: Comparison of antiaddictive efficacy, toxicity, and mechanisms of action","volume":"914","author":"Glick","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.vascn.2016.04.012_bb0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcph.404","article-title":"Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability","volume":"55","author":"Glue","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0080","series-title":"Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients","author":"Glue","year":"2016"},{"key":"10.1016\/j.vascn.2016.04.012_bb0085","article-title":"Pharmacodynamics and therapeutic applications of iboga and ibogaine","volume":"70","author":"Goutarel","year":"1993","journal-title":"Psychedelic Monogr. Essays"},{"issue":"1","key":"10.1016\/j.vascn.2016.04.012_bb0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pnpbp.2003.09.026","article-title":"Anticonvulsant and antiepileptogenic effects of GABAA receptor ligands in pentylenetetrazole-kindled mice","volume":"28","author":"Hansen","year":"2004","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.vascn.2016.04.012_bb0095","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0022-3565(24)29466-0","article-title":"Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: Mechanism and site of action","volume":"298","author":"Huang","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2016.04.012_bb0100","first-page":"67","article-title":"Pentylentetrazol associated changes of hippocampal neurons in immature rats","volume":"108","author":"Jandov\u00e1","year":"2007","journal-title":"Prague Medical Report"},{"issue":"1","key":"10.1016\/j.vascn.2016.04.012_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/1756285610395653","article-title":"Myoclonic disorders: A practical approach for diagnosis and treatment","volume":"4","author":"Kojovic","year":"2011","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"10.1016\/j.vascn.2016.04.012_bb0110","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1152\/physiolgenomics.00164.2002","article-title":"Evaluation and applications of radiotelemetry in small laboratory animals","volume":"13","author":"Kramer","year":"2003","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.vascn.2016.04.012_bb0115","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.mehy.2006.02.050","article-title":"Fatalities after taking ibogaine in addiction treatment could be related to sudden cardiac death caused by autonomic dysfunction","volume":"67","author":"Maas","year":"2006","journal-title":"Medical Hypotheses"},{"key":"10.1016\/j.vascn.2016.04.012_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/0960327107087802","article-title":"Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review","volume":"27","author":"Maciulaitis","year":"2008","journal-title":"Human & Experimental Toxicology"},{"issue":"3","key":"10.1016\/j.vascn.2016.04.012_bb0130","doi-asserted-by":"crossref","first-page":"PL45","DOI":"10.1016\/0024-3205(95)00273-9","article-title":"Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin","volume":"57","author":"Mash","year":"1995","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/j.vascn.2016.04.012_bb0135","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(95)11608-Y","article-title":"Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex","volume":"192","author":"Mash","year":"1995","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.vascn.2016.04.012_bb0140","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","article-title":"Ibogaine: Complex pharmacokinetics, concerns for safety, and preliminary efficacy measures","volume":"914","author":"Mash","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/j.vascn.2016.04.012_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0099-9598(01)56012-5","article-title":"Ibogaine in the treatment of heroin withdrawal","volume":"56","author":"Mash","year":"2001","journal-title":"The Alkaloids. Chemistry and Biology"},{"key":"10.1016\/j.vascn.2016.04.012_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.vascn.2015.04.001","article-title":"Assessment of seizure risk in pre-clinical studies: Strengths and limitations of the electroencephalogram (EEG)","volume":"75","author":"Metea","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2016.04.012_bb0155","first-page":"764","article-title":"Cytochrome P4502D6 catalyzes the O-demethylation of the psychoactive alkaloid ibogaine to 12-hydroxyibogamine","volume":"26","author":"Obach","year":"1998","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.vascn.2016.04.012_bb0160","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0091-3057(96)00383-8","article-title":"Sex differences in ibogaine antagonism of morphine-induced locomotor activity and in ibogaine brain levels and metabolism","volume":"57","author":"Pearl","year":"1997","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"6","key":"10.1016\/j.vascn.2016.04.012_bb0165","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jsr.12189","article-title":"Sleep electroencephalographic characteristics of the cynomolgus monkey measured by telemetry","volume":"23","author":"Rachalski","year":"2014","journal-title":"Journal of Sleep Research"},{"issue":"Suppl. 2","key":"10.1016\/j.vascn.2016.04.012_bb0170","first-page":"ii2","article-title":"EEG in the diagnosis, classification, and management of patients with epilepsy","volume":"76","author":"Smith","year":"2005","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.vascn.2016.04.012_bb0175","doi-asserted-by":"crossref","unstructured":"Staley JK, Ouyang Q, Pablo J, Hearn WL, Flynn DD, Rothman RB, Rice KC, Mash DC. Pharmacological screen for activities of 12-hydroxyibogamine: A primary metabolite of the indole alkaloid ibogaine. Psychopharmacology. 1996 Sep;127(1):10\u20138.","DOI":"10.1007\/BF02805969"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871916300399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:02:26Z","timestamp":1761004946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871916300399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":34,"alternative-id":["S1056871916300399"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2016.04.012","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2016.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}